LIQUIDIA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.29 USD | +2.76% |
|
-1.68% | +2.16% |
| May. 13 | Liquidia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 01 | Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension | MT |
Presenter SpeechGreg Harrison (Analysts)Hello, everyone. Welcome to day 1 of the Bank of Ameri...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.96
USD
Average target price
24.14
USD
Spread / Average Target
+101.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.16% | 914M | |
| +31.37% | 588B | |
| -2.60% | 364B | |
| +20.83% | 326B | |
| +5.69% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.77% | 167B | |
| +0.10% | 161B |
- Stock Market
- Equities
- LQDA Stock
- News Liquidia Corporation
- Transcript : Liquidia Corporation Presents at Bank of America Securities 2023 Healthcare Conference, May-09-2023 09
